Hutchmed (China) Ltd. HCM
What this company does
Written from the business description in HUTCHMED (China) Ltd's annual report to the U.S. Securities and Exchange Commission, filed 5 March 2026. Every sentence was checked against that document before publication.
Revenue compounded at +19.2% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Each USD of equity produced 46 cents of profit this year.
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.5 | 0.6 | 0.8 | 0.4 | 0.4 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.1 |
| Operating income $B | −0.0 | −0.0 | 0.0 | −0.4 | −0.3 | −0.2 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 |
| EBITDA $B | −0.0 | −0.0 | 0.0 | −0.4 | −0.3 | −0.2 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 |
| Income tax $B | 0.1 | 0.0 | 0.0 | −0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net income $B | 0.5 | 0.0 | 0.1 | −0.4 | −0.2 | −0.1 | −0.1 | −0.1 | −0.0 | 0.0 | 0.0 | −0.0 |
| Free cash flow $B | −0.1 | −0.0 | 0.2 | −0.3 | −0.2 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | 0.0 |
| EPS, diluted $ | 0.52 | 0.04 | 0.12 | −0.43 | −0.25 | −0.18 | −0.16 | −0.11 | −0.04 | 0.20 | −0.64 | −0.62 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | 45.7 | 5.1 | 15.0 | −45.2 | −26.5 | −32.6 | −31.3 | −17.6 | −8.3 | 8.7 | 9.6 | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Reconciled in 12 of 19 fiscal years. 41 checks could not be computed.